CoChat

Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials

Tran, Susan, Retnakaran, Ravi, Zinman, Bernard, Kramer, Caroline K. · 2018 · Diabetes, Obesity and Metabolism
Cited by 51

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aims: Glucagon‐like peptide‐1 (GLP‐1) agonists and dipeptidyl peptidase‐4 (DPP‐4) inhibitors are both incretin‐based therapies for type 2 diabetes (T2DM) but have distinct efficacy and side effect profiles. We thus performed a systematic review and meta‐analysis to compare the effects of GLP‐1 agonists to DPP‐4 inhibitors on glycaemic control, weight and incidence of adverse events in adults with T2DM. We also sought to determine whether there was any additional effect in switching from DPP‐4 inhibitor to GLP‐1 agonist. Materials and methods: We systematically searched PubMed, Embase and ClinicalTrials.gov for (1) randomized controlled trials (RCTs) comparing any GLP‐1 agonist to any DPP‐4 inhibitor and (2) interventional studies where a DPP‐4 inhibitor was switched to a GLP‐1 agonist. We assessed pooled data using random‐effects model (CRD42017057115). Results: The pooled analysis of 13 RCTs ( n = 4330) showed that, compared to DPP‐4 inhibitors, GLP‐1 agonists yielded a greater mean reduction in glycated haemoglobin (HbA1c) of −0.41% (95% CI −0.53 to −0.30) and in weight of −2.15 kg (−3.04 to −1.27). GLP‐1 agonists were associated with greater likelihood of gastrointestinal side effects with no increased risk of hypoglycaemia. In 5 interventional studies ( n = 433), switching from DPP‐4 inhibitor to GLP‐1 agonist yielded further mean reduction in HbA1c of −0.69% (−1.03 to −0.35) and in weight of −2.25 kg (−3.12 to −1.38). Conclusions: GLP‐1 agonists yield greater reduction in HbA1c and weight as compared to DPP‐4 inhibitors, with increased incidence of gastrointestinal symptoms but not hypoglycaemia. Replacing a DPP‐4 inhibitor with GLP‐1 agonist provides additional benefits in glycaemic control and weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13137

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 51

Metadata

Authors
Tran, S., Retnakaran, R., Zinman, B., & Kramer, C. K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-01-24
Volume
20
Issue
S1
Pages
68-76
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2791740462
Cited by
51
References
14
FWCI
4.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1111/dom.13137
The paper
Tran, S., Retnakaran, R., Zinman, B., & Kramer, C. K. (2018). Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.